カーベディロールは,ヒトの衰弱した心筋膜における高酸化ストレスを減少させます
Kazufumi Nakamura1, Kengo Kusano, Yoichi Nakamura
1Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan. ichibun@cc.okayama-u.ac.jp
Circulation
|June 19, 2002
まとめ
脂質過酸化物の上昇によって示される酸化ストレスが,ヒトの心不全に存在します. カーベディロールによる治療は,この酸化ストレスを有意に減らし,心臓の機能を改善しました.
科学分野:
- 心臓病学 心臓病学
- バイオケミストリー バイオケミストリー
- 病理生理学 病理生理学とは
背景:
- 酸化ストレス (Oxidative stress) は,心不全の発達における疑われる要因である.
- 人間の衰弱した心臓における酸化ストレスに関する直接的な証拠は限られている.
- 抗酸化特性を有するベータブロッカーであるカルベディロールが心筋の酸化ストレスに及ぼす影響は不明である.
研究 の 目的:
- 拡張性心筋症 (DCM) の患者の心筋内における高血脂過酸化物レベルを調査する.
- DCM患者における心筋脂質過酸化に対するカルベディロールの効果を評価する.
主な方法:
- 脂質過酸化のマーカーである4-ヒドロキシ-2-ノンネナル (HNE) 改変タンパク質の免疫ヒスト化学分析.
- 23人のDCM患者と13人の対照群のサンプルを分析した.
- 11人のDCM患者はカルベディロールで治療され,再評価されました.
主要な成果:
- DCMの患者では,対照群 (P<0.0001) と比較して,心筋のHNE変異タンパク質のレベルが著しく高いことが観察されました.
- DCM患者における心筋筋細胞のサイトゾールにHNE変異タンパク質発現が検出されました.
- カーベディロール治療 (平均9ヶ月) は,心筋のHNE-改変タンパク質レベルを40% (P<0.005) 低下させた.
結論:
- 衰えつつある人間の心筋は,高レベルの酸化ストレスを示します.
- カーベディロールの投与は,心臓における酸化的ストレスを効果的に軽減します.
- カーベディロール治療は,心不全患者の心臓機能の改善につながります.
さらに関連する動画
08:35Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
07:40Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
関連する概念動画
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:26Imbalances in Cardiac Output
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...